Study of Olverembatinib (HQP1351) in Patients With CML-CP

Summary

Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.

Eligibility

Inclusion Criteria

Patients eligible for inclusion in this study must meet all of the following criteria:

1. Age ≥ 18 years old
2. Diagnosis of CML-CP
3. Part A: Previously treated with at least two approved TKIs; Part B: T315I mutation at screening and previously treated with at least one approved TKI, with no other effective and/or tolerable therapies available
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
5. Patient has adequate organ function

Exclusion Criteria

Patients eligible for this study must not meet any of the following criteria:

1. For Part A only: T315I or V299L mutation at any time prior to starting study treatment
2. Active infection that requires systemic drug therapy
3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of study drugs
4. Previous treatment with or known / suspected hypersensitivity to olverembatinib or any of its excipients
5. Previous treatment with or known / suspected hypersensitivity to bosutinib or any of its excipients
6. Pregnant or nursing (lactating) women

Conditions4

Interventions2

Locations50 sites

Find trials near these locations

Related trials

• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) — Canadian Cancer Trials Group
• Asciminib Roll-over Study — Novartis Pharmaceuticals
• A Study of Olverembatinib in SDH-deficient GIST. — Ascentage Pharma Group Inc.
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL — Institute of Hematology & Blood Diseases Hospital, China
• Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL — Institute of Hematology & Blood Diseases Hospital, China
• Newly-diagnosed Pediatric Ph-positive B-ALL Protocol — Institute of Hematology & Blood Diseases Hospital, China
• Olverembatinib for FGFR1-rearranged Neoplasms — The First Affiliated Hospital of Soochow University
• Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML — Ascentage Pharma Group Inc.

Browse More Trials